Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Analysis of cyclin E and CDK2 in ovarian cancer: gene amplification and RNA overexpression.

Authors: Marone, M  Scambia, G  Giannitelli, C  Ferrandina, G  Masciullo, V  Bellacosa, A  Benedetti-Panici, P  Mancuso, S 
Citation: Marone M, etal., Int J Cancer. 1998 Jan 5;75(1):34-9.
Pubmed: (View Article at PubMed) PMID:9426687

Cyclins and their associated kinases (cdks) play a key role in controlling the cell cycle, a process whose disregulation can potentially lead to uncontrolled cell growth and hence to cancer. We have studied the role of both cyclin E and its associated kinase cdk2 in ovarian cancer. Primary, metastatic, recurrent and benign ovarian tumors were screened for cyclin E and cdk2 gene amplification. Cyclin E was shown to be amplified in 21% and cdk2 in 6.4% of the cases analyzed. Cyclin E and cdk2 RNA expression levels were determined by semi-quantitative RT-PCR analysis in a partially overlapping series of samples and compared to the expression levels of normal ovarian surface epithelial cells. Cyclin E RNA was overexpressed in 29.5% and cdk2 in 6.5% of ovarian tumors tested. We determined that in most cases gene amplification leads to higher RNA levels for cyclin E and that the overall levels of cyclin E and cdk2 RNA were correlated. We hypothesize that cyclin E and cdk2 are, in part co-regulated and that they may concur to ovarian tumor development.


Disease Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 2298989
Created: 2008-08-08
Species: All species
Last Modified: 2008-08-08
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.